Adenovirus Capsid-display of the Retro-oriented Human Complement Inhibitor DAF Reduces Ad Vector-triggered Immune Responses in Vitro and in Vivo

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2010 Jun 1

PMID 20511542

Citations 25

Authors

Sergey S Seregin

Yasser A Aldhamen

Daniel M Appledorn

Zachary C Hartman

Nathaniel J Schuldt

Jeannine Scott

Sarah Godbehere

Haixiang Jiang

Michael M Frank

Andrea Amalfitano

Affiliations

Soon will be listed here.

Abstract

Adenovirus (Ad) vectors are widely used in human clinical trials. However, at higher dosages, Ad vector-triggered innate toxicities remain a major obstacle to many applications. Ad interactions with the complement system significantly contribute to innate immune responses in several models of Ad-mediated gene transfer. We constructed a novel class of Ad vectors, genetically engineered to "capsid-display" native and retro-oriented versions of the human complement inhibitor decay-accelerating factor (DAF), as a fusion protein from the C-terminus of the Ad capsid protein IX. In contrast to conventional Ad vectors, DAF-displaying Ads dramatically minimized complement activation in vitro and complement-dependent immune responses in vivo. DAF-displaying Ads did not trigger thrombocytopenia, minimized endothelial cell activation, and had diminished inductions of proinflammatory cytokine and chemokine responses. The retro-oriented display of DAF facilitated the greatest improvements in vivo, with diminished activation of innate immune cells, such as dendritic and natural killer cells. In conclusion, Ad vectors can capsid-display proteins in a manner that not only retains the functionality of the displayed proteins but also potentially can be harnessed to improve the efficacy of this important gene transfer platform for numerous gene transfer applications.

Citing Articles

Thrombotic Microangiopathy as an Emerging Complication of Viral Vector-Based Gene Therapy.

Schwotzer N, El Sissy C, Desguerre I, Fremeaux-Bacchi V, Servais L, Fakhouri F Kidney Int Rep. 2024; 9(7):1995-2005.

PMID: 39081755 PMC: 11284364. DOI: 10.1016/j.ekir.2024.04.024.

The Immune System-A Double-Edged Sword for Adenovirus-Based Therapies.

Wallace R, Bliss C, Parker A Viruses. 2024; 16(6).

PMID: 38932265 PMC: 11209478. DOI: 10.3390/v16060973.

Engineered Oncolytic Adenoviruses: An Emerging Approach for Cancer Therapy.

Tan E, Abd-Aziz N, Poh C, Tan K Pathogens. 2022; 11(10).

PMID: 36297203 PMC: 9608483. DOI: 10.3390/pathogens11101146.

Adenoviral delivery of an immunomodulatory protein to the tumor microenvironment controls tumor growth.

OConnell P, Blake M, Pepelyayeva Y, Hyslop S, Godbehere S, Angarita A Mol Ther Oncolytics. 2022; 24:180-193.

PMID: 35036523 PMC: 8741417. DOI: 10.1016/j.omto.2021.12.004.

Untangling the Intricacies of Infection, Thrombosis, Vaccination, and Antiphospholipid Antibodies for COVID-19.

Cimolai N SN Compr Clin Med. 2021; 3(10):2093-2108.

PMID: 34179695 PMC: 8218573. DOI: 10.1007/s42399-021-00992-3.

References

Mollnes T, Song W, Lambris J . Complement in inflammatory tissue damage and disease. Trends Immunol. 2002; 23(2):61-4. DOI: 10.1016/s1471-4906(01)02129-9. View

Appledorn D, McBride A, Seregin S, Scott J, Schuldt N, Kiang A . Complex interactions with several arms of the complement system dictate innate and humoral immunity to adenoviral vectors. Gene Ther. 2008; 15(24):1606-17. PMC: 11112971. DOI: 10.1038/gt.2008.114. View

Hartman Z, Black E, Amalfitano A . Adenoviral infection induces a multi-faceted innate cellular immune response that is mediated by the toll-like receptor pathway in A549 cells. Virology. 2006; 358(2):357-72. DOI: 10.1016/j.virol.2006.08.041. View

Kemper C, Atkinson J . T-cell regulation: with complements from innate immunity. Nat Rev Immunol. 2006; 7(1):9-18. DOI: 10.1038/nri1994. View

Harris C, Spiller O, Morgan B . Human and rodent decay-accelerating factors (CD55) are not species restricted in their complement-inhibiting activities. Immunology. 2000; 100(4):462-70. PMC: 2327033. DOI: 10.1046/j.1365-2567.2000.00066.x. View

Mittl P, Deillon C, Sargent D, Liu N, Klauser S, Thomas R . The retro-GCN4 leucine zipper sequence forms a stable three-dimensional structure. Proc Natl Acad Sci U S A. 2000; 97(6):2562-6. PMC: 15968. DOI: 10.1073/pnas.97.6.2562. View

Shapiro N, Yano K, Sorasaki M, Fischer C, Shih S, Aird W . Skin biopsies demonstrate site-specific endothelial activation in mouse models of sepsis. J Vasc Res. 2009; 46(5):495-502. DOI: 10.1159/000210662. View

Seregin S, Hartman Z, Appledorn D, Godbehere S, Jiang H, Frank M . Novel adenovirus vectors 'capsid-displaying' a human complement inhibitor. J Innate Immun. 2010; 2(4):353-9. PMC: 2895756. DOI: 10.1159/000284368. View

Seregin S, Appledorn D, McBride A, Schuldt N, Aldhamen Y, Voss T . Transient pretreatment with glucocorticoid ablates innate toxicity of systemically delivered adenoviral vectors without reducing efficacy. Mol Ther. 2009; 17(4):685-96. PMC: 2835110. DOI: 10.1038/mt.2008.297. View

10.

He T, Zhou S, DA COSTA L, Yu J, Kinzler K, Vogelstein B . A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A. 1998; 95(5):2509-14. PMC: 19394. DOI: 10.1073/pnas.95.5.2509. View

11.

Mollnes T, Kirschfink M . Strategies of therapeutic complement inhibition. Mol Immunol. 2005; 43(1-2):107-21. DOI: 10.1016/j.molimm.2005.06.014. View

12.

Schauber-Plewa C, Simmons A, Tuerk M, Pacheco C, Veres G . Complement regulatory proteins are incorporated into lentiviral vectors and protect particles against complement inactivation. Gene Ther. 2004; 12(3):238-45. DOI: 10.1038/sj.gt.3302399. View

13.

Schiedner G, Bloch W, Hertel S, Johnston M, Molojavyi A, Dries V . A hemodynamic response to intravenous adenovirus vector particles is caused by systemic Kupffer cell-mediated activation of endothelial cells. Hum Gene Ther. 2003; 14(17):1631-41. DOI: 10.1089/104303403322542275. View

14.

Jiang H, Wang Z, Serra D, Frank M, Amalfitano A . Recombinant adenovirus vectors activate the alternative complement pathway, leading to the binding of human complement protein C3 independent of anti-ad antibodies. Mol Ther. 2004; 10(6):1140-2. DOI: 10.1016/j.ymthe.2004.08.015. View

15.

Parks R . Adenovirus protein IX: a new look at an old protein. Mol Ther. 2004; 11(1):19-25. DOI: 10.1016/j.ymthe.2004.09.018. View

16.

Ng P, Graham F . Construction of first-generation adenoviral vectors. Methods Mol Med. 2002; 69:389-414. DOI: 10.1385/1-59259-141-8:389. View

17.

Hartman Z, Kiang A, Everett R, Serra D, Yang X, Clay T . Adenovirus infection triggers a rapid, MyD88-regulated transcriptome response critical to acute-phase and adaptive immune responses in vivo. J Virol. 2006; 81(4):1796-812. PMC: 1797572. DOI: 10.1128/JVI.01936-06. View

18.

Huser A, Rudolph M, Hofmann C . Incorporation of decay-accelerating factor into the baculovirus envelope generates complement-resistant gene transfer vectors. Nat Biotechnol. 2001; 19(5):451-5. DOI: 10.1038/88122. View

19.

Muruve D, Barnes M, Stillman I, Libermann T . Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. Hum Gene Ther. 1999; 10(6):965-76. DOI: 10.1089/10430349950018364. View

20.

Favoreel H, Van de Walle G, Nauwynck H, Pensaert M . Virus complement evasion strategies. J Gen Virol. 2003; 84(Pt 1):1-15. DOI: 10.1099/vir.0.18709-0. View